Wilmington, DE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will ...

Jeff Johnson, an analyst from Robert W. Baird, maintained the Buy rating on Enovis (ENOV – Research Report). The associated price target is $64.00. Jeff Johnson has given his Buy rating due to a ...